CVN424 Phase 3 ARISE Trial for Parkinson's Disease

<div class="infobox infobox-trial">
<div class="infobox-header">ARISE Trial</div>
<div class="infobox-row">
<div class="infobox-label">NCT Number</div>
<div class="infobox-value">NCT06553027</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Phase</div>
<div class="infobox-value">Phase 3</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Status</div>
<div class="infobox-value">Recruiting</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Sponsor</div>
<div class="infobox-value">Cerevance</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Intervention</div>
<div class="infobox-value">CVN424 (GPR6 inverse agonist)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Indication</div>
<div class="infobox-value">Parkinson's Disease (Motor Complications)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Enrollment</div>
<div class="infobox-value">~400 participants (planned)</div>
</div>
</div>

Overview

CVN424 is a novel non-dopaminergic drug candidate being developed by Cerevance for the treatment of Parkinson's disease motor complications. It is a highly selective inverse agonist of GPR6, a G-protein-coupled receptor highly expressed in striatal medium spiny neurons (MSNs) of the indirect pathway[@gpr][@cerevance].

<div class="infobox infobox-trial">
<div class="infobox-header">ARISE Trial</div>
<div class="infobox-row">
<div class="infobox-label">NCT Number</div>
<div class="infobox-value">NCT06553027</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Phase</div>
<div class="infobox-value">Phase 3</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Status</div>
<div class="infobox-value">Recruiting</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Sponsor</div>
<div class="infobox-value">Cerevance</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Intervention</div>
<div class="infobox-value">CVN424 (GPR6 inverse agonist)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Indication</div>
<div class="infobox-value">Parkinson's Disease (Motor Complications)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Enrollment</div>
<div class="infobox-value">~400 participants (planned)</div>
</div>
</div>

Overview

CVN424 is a novel non-dopaminergic drug candidate being developed by Cerevance for the treatment of Parkinson's disease motor complications. It is a highly selective inverse agonist of GPR6, a G-protein-coupled receptor highly expressed in striatal medium spiny neurons (MSNs) of the indirect pathway[@gpr][@cerevance].

The Phase 3 ARISE trial (NCT06553027) is evaluating CVN424 as an adjunctive therapy for Parkinson's disease patients experiencing motor fluctuations (OFF time). This represents a fundamentally different approach from traditional dopamine agonists, potentially offering efficacy with reduced dopaminergic side effects[@cvn2022].

Parkinson's disease affects approximately 10 million people worldwide and is characterized by the progressive loss of dopaminergic neurons in the substantia nigra. While dopaminergic therapies (levodopa, dopamine agonists) are effective initially, long-term use leads to motor complications including OFF episodes (periods when medication wears off and motor symptoms return) and dyskinesias (involuntary movements).

Mechanism of Action

GPR6 Target Biology

GPR6 is an orphan G-protein-coupled receptor with a unique distribution profile:

Why GPR6 for Parkinson's Disease?

The GPR6 target offers several theoretical advantages over dopaminergic approaches:

• Psychosis and hallucinations
• Impulse control disorders
• Sleep attacks
• Peripheral edema

NETSseq Platform

CVN424 was discovered using Cerevance's NETSseq (Nuclear Enriched Transcript Sequencing) platform, which allows for the identification of novel drug targets with highly specific expression patterns in the brain[@cerevance]. This approach identified GPR6 as a target enriched in the indirect pathway neurons.

Clinical Development Timeline

| Milestone | Date |
|-----------|------|
| First-in-human dosing (Phase 1) | September 2018 |
| Phase 2 trial initiated (ASCEND) | December 2019 |
| Positive Phase 2 results | March 2022 |
| Phase 2 ASCEND topline (AD/PD 2025) | April 2025 |
| Phase 3 ARISE first patient dosed | November 2024 |
| Expected Phase 3 topline data | First half 2026 |

Phase 2 ASCEND Trial Results

The Phase 2 ASCEND trial evaluated CVN424 as monotherapy for early-stage Parkinson's disease[@cvn2022]:

Efficacy Results

• OFF time reduction: 1.73 hours reduction in OFF time versus baseline (p<0.01)
• 45% improvement: 45% increase in OFF time efficacy compared to baseline
• Low dyskinesia rates: Significantly lower rates of dopaminergic side effects compared to standard treatments

Safety Profile

• Well-tolerated: CVN424 demonstrated a favorable safety profile in Phase 2
• Reduced side effects: Up to 150% reduction in common side effects compared to current treatment options
• Low rates of: Impulse control disorders, hallucinations, and peripheral edema

Phase 3 ARISE Trial Design

The Phase 3 ARISE trial (NCT06553027) is a randomized, double-blind, placebo-controlled study[@cvn2022]:

Trial Structure

| Parameter | Details |
|-----------|---------|
| Phase | Phase 3 |
| Design | Randomized, double-blind, placebo-controlled |
| Population | Parkinson's disease with motor complications |
| Intervention | CVN424 oral tablets |
| Primary Endpoint | Change in OFF time from baseline |
| Secondary Endpoints | ON time, UPDRS scores, dyskinesia scales |

Expected Enrollment

Approximately 400 participants with Parkinson's disease experiencing motor fluctuations will be enrolled at multiple sites globally.

Comparison with Other PD Motor Complications Treatments

| Treatment | Mechanism | Efficacy (OFF reduction) | Key Concerns |
|-----------|-----------|-------------------------|--------------|
| CVN424 (ARISE) | GPR6 inverse agonist | 1.73 hrs (Phase 2) | Novel mechanism |
| Pramipexole | D3/D2 agonist | 1-2 hrs | ICD, hallucinations |
| Rotigotine | D3/D2 agonist | 1-2 hrs | Skin reactions |
| Apomorphine | D1/D2 agonist | 2-4 hrs | Injection site reactions |
| Levodopa/carbidopa/entacapone | COMT inhibitor | 0.5-1 hr | Dyskinesias |

CVN424 represents a fundamentally different approach by targeting the indirect pathway directly rather than replacing dopamine, potentially offering efficacy with improved side effect profile.

Company Information

Cerevance is a privately held pharmaceutical company focused on developing novel therapeutics for central nervous system disorders using their proprietary NETSseq platform[@cerevance]. The company was founded with the goal of identifying brain-selective drug targets with improved therapeutic windows.

Leadership and Funding

• Headquartered in Cambridge, Massachusetts
• Backed by leading life sciences investors
• Focused on Parkinson's disease, Alzheimer's disease, and other neurological conditions

Cross-References

Related Mechanisms

• Basal Ganglia Circuit in Parkinson's Disease
• Parkinson's Disease OFF Time
• Indirect Pathway in Movement Control

Related Treatments

• Dopamine Agonists in Parkinson's Disease
• Levodopa Therapy
• [COMT Inhibitors](/therapeutics/comt-inhibitors)

Related Conditions

• [Parkinson's Disease](/diseases/parkinsons-disease)
• Parkinson's Disease Motor Complications
• Dyskinesias

External Links

• [ClinicalTrials.gov - NCT06553027](https://clinicaltrials.gov/study/NCT06553027)
• [Cerevance Pipeline](https://www.cerevance.com/pipeline/)
• [Parkinson's Foundation - Motor Fluctuations](https://www.parkinson.org/)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving CVN424 Phase 3 ARISE Trial for Parkinson's Disease discovered through SciDEX knowledge graph analysis: